openPR Logo

Press Releases from ICRC-Weyer GmbH (10 total)

ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group

In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process. The decision to form MEDIS Research Group came as a reaction to a shift in the market towards

ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies

In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing. ‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We

Clinical CRO ICRC-Weyer To Boost Drug Safety Services For Investigator Trials

The Berlin-based clinical contract research organization (CRO), ICRC-Weyer GmbH, has announced it will boost its drug-safety related Pharmacovigilance Services for Investigator-Initiated Trials amid an increasing demand by trial sponsors. An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to large and mid-sized pharmaceutical trial sponsors. ‘A large

ICRC-Weyer To Enhance Pharmacovigilance Risk Management

The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments. The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives

ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012

The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcing clinical services. According to J. Daniel Weyer, Managing Director at ICRC-Weyer, the success results from the hard work of a devoted team combined with the company’s constant enhancements to their existing services portfolio. ‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted

Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials

ICRC-Weyer’s recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took place at the British Embassy in Berlin on September 5th, 2012 was attended by two members of the ICRC-Weyer team. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in

Drug Development Requires Flexibility In Clinical Trial Design: Interview With I …

In a recent interview, Prof Dr. Geerd Weyer of ICRC-Weyer GmbH, a Berlin-based clinical contract research organization, claims that every clinical trial is unique and must be designed and treated as such. What would accelerate drug development and delivery/time to market? In the last few years, many large pharmaceutical companies have been contracting out clinical development services to single, globally acting service providers. They tend to believe that the globalization of

New Medical Coding Procedures At Clinical CRO ICRC-Weyer

ICRC-Weyer GmbH has announced an enhancement to their medical coding procedures for drug development processes. Until recently, the company had been utilizing limited licenses for the coding dictionary of the World Health Organization WHO (WHO DD/WHO Drug). WHO DD is an international classification of medicines created by the WHO Programme for International Drug Monitoring and managed by the Uppsala Monitoring Centre. It is used by pharmaceutical companies, clinical trial organizations

ICRC-Weyer Enhance Medical Data Management Services

ICRC-Weyer has enhanced its expert medical data management services in order to strengthen its position as a leading provider of data management services in the market. The services are being delivered by knowledgeable medical staff who are responsible for manual medical data validation, medical coding, planning and organisation of ICRC-Weyer’s specialist medical review services. “The medical review service contains the review of clinical databases by well-trained medical staff which take place

ICRC-Weyer To Adjust Services Portfolio In Light Of New European Health Claim Re …

ICRC-Weyer GmbH has announced an adjustment of their services portfolio which will enable manufacturers of dietary supplements and functional foods to benefit from the German-based CRO’s expertise and resources by conducting clinical trials for their products. The announcement was made following a decision by the European Parliamentary Committee on Environment, Public Health and Food Safety (ENVI) to pass a list of 222 health claims for dietary food supplements after officially

Go To Page:   1 2 3 4 5 6 7 8 9 10